Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-01-21
DOI
10.3389/fonc.2019.00019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
- (2018) Alex Karlsson-Parra et al. PHARMACEUTICAL RESEARCH
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses
- (2017) Grammatiki Fotaki et al. OncoImmunology
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
- (2017) Anna Laurell et al. Journal for ImmunoTherapy of Cancer
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Potentiality of immunotherapy against hepatocellular carcinoma
- (2015) Nobuhiro Tsuchiya WORLD JOURNAL OF GASTROENTEROLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
- (2011) Katherine A. McGlynn et al. Clinics in Liver Disease
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
- (2011) Andreas Draube et al. PLoS One
- Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
- (2010) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolic syndrome and hepatocellular carcinoma
- (2009) Abby B. Siegel et al. CANCER
- Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages
- (2009) Dorothée Duluc et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
- (2008) K. Gustafsson et al. CANCER RESEARCH
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search